.jpg)
CAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisition
Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, manufacturing considerations have prompted Lyell Immunopharma to cut staff at its new subsidiary and mothball a California facility picked up in the deal.
Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, manufacturing considerations have prompted Lyell Immunopharma to cut staff at its new subsidiary and mothball a California facility picked up in the deal.
